跳至主要内容
临床试验/NCT03013634
NCT03013634Unknown不适用

Protective Effects of Dexmedetomidine on Myocardial Injury During Liver Transplantation

Tianjin First Central Hospital1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2016年10月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
发起方
入组人数
100
试验地点
1
主要终点
The incidence of cardiac complications

研究概览

简要总结

The purpose of this study was to evaluate the protective effect of dexmedetomidine on myocardial injury during liver transplantation

详细描述

Liver transplantation surgery may lead to myocardial injury. Dexmedetomidine, a highly specific α2-adrenoeptor agonist, has sedative and analgesic properties without significant respiratory depression at the clinically approved dosage. Some investigations indicated that dexmedetomidine was able to protect the myocardium via improving the activity of Na+-K+-adenosine triphosphate enzyme and Ca2+-adenosine triphosphate, alleviating inflammation reaction and avoiding Ca2+ overload. However, the effect and the mechanism of dexmedetomidine on myocardial injury during liver transplantation remain unclear.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • End stage liver disease scheduled for liver transplantation in Tianjin First Center Hospital

排除标准

  • Pre-existing respiratory failure,renal failure,hepatic encephalopathy

研究组 & 干预措施

Dexmedetomidine Group

Experimental

Dexmedetomidine infusion:loading 0.5ug/kg for 10min, then 0.5 ug/kg/h until the end of operation.

干预措施: Dexmedetomidine (Drug)

Normal saline Group

Placebo Comparator

Equal volume normal saline substitute for dexmedetomidine

干预措施: Normal saline (Drug)

结局指标

主要结局

The incidence of cardiac complications

时间窗: from anesthesia induction to 24 hours after operation

Peri-operative mortality

时间窗: through study completion, an average of 5 weeks

次要结局

  • Evidences of Clinically Definite Myocardial Injury Confirmed by Electrochemiluminescence(before skin incision, 0.5 hour min after anhepatic, 2 hours of neohepatic stage,the end of surgery,24 hours after operation)

研究者

发起方
Tianjin First Central Hospital
申办方类型
Other
责任方
Principal Investigator
主要研究者

Wenli Yu

Wenli Yu,PhD ,Department of Anesthesiology,Tianjin First Center Hospital

Tianjin First Central Hospital

研究点 (1)

Loading locations...

相似试验